Clinical trial
Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer
NCT00052507 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00052507 |
|---|---|
| Title | Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer |
| Official title | A Phase II Study Of PS-341 In Patients With Metastatic Colorectal Cancer |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | bortezomib |
| Start date | Jan 1, 2003 |
| Primary completion | Aug 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 23, 2015 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: